Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

• Main Authors: Catharina Busch, Dinah Zur, Samantha Fraser-Bell, Inês Laíns, Ana Rita Santos, Marco Lupidi, Carlo Cagini, Pierre Henry Gabrielle, Aude Couturier, Valérie Mané-Tauty, Ermete Giancipoli, Giuseppe D.Amico Ricci, Zafer Cebeci, Patricio J. Rodríguez-Valdés, Voraporn Chaikitmongkol, Atchara Amphornphruet, Isaac Hindi, Kushal Agrawal, Jay Chhablani, Anat Loewenstein, Matias Iglicki, Matus Rehak
• Format: Journal
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046451948&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/58215
• Institution: Chiang Mai University

© 2018, Springer-Verlag Italia S.r.l., part of Springer Nature. Aims: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEG...